IMV gets OK for RSV vaccine human trials in Canada

Immunovaccine Inc. (IMV) said on Tuesday that it received approval from Health Canada to begin Phase I clinical trials on a DepoVax-based test vaccine against respiratory syncytial virus (RSV).

In this first phase, 40 healthy, adult volunteers between the ages of 50 and 64 will be used. Testing will be conducted at the Canadian Center for Vaccinology in Halifax, and Dr. Joanne Langley will lead the research team.

RSV is a respiratory infection that is one of the leading causes of pneumonia in elderly patients. It primarily affects older patients, infants and individuals with a compromised immune system. The World Health Organization considers the potential vaccine a high priority.

“This trial is a significant milestone for Immunovaccine as it represents the first clinical use of DepoVax for the prevention of an infectious disease in healthy people," IMV CEO Dr. Marc Mansour said. "We expect the results from this study to demonstrate the clinical applicability of DepoVax that could be extended to other infectious-disease applications."

The company currently is conducting animal testing against anthrax bacteria and Ebola viruses using similar DepoVax test vaccines. The vaccines are in the proof-of-concept stage in partnership with the National Institutes of Health.

Organizations in this Story

National Institutes of Health

Want to get notified whenever we write about National Institutes of Health ?
Next time we write about National Institutes of Health, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.